Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xiaofeng Xuanqiao granules for perennial allergic rhinitis in children (lung meridian wind-cold pattern)
CTR20232746Phase 2Completed
- Sponsor
- Suzhong Pharmaceutical Group Co., Ltd.
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Xiaofeng Xuanqiao in allergic rhinitis (AR), sponsored by Suzhong Pharmaceutical Group Co., Ltd.. Started Sep 2023; status: completed.
02
Drugs
Xiaofeng Xuanqiao
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on CTR20232746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232746.